Pub Date : 2026-02-01DOI: 10.1016/j.clinre.2026.102778
Siri A. Urquhart, Luis E. Ospina Velasquez, John B. Kisiel, Nayantara Coelho-Prabhu
Background and Aims
A direct causal association between inflammatory bowel disease (IBD) and appendiceal neoplasm (AN) is unclear.
Methods
Patients with IBD and AN were identified from 1992 to 2023 using bioinformatics and natural language processing tools.
Results
Thirty-one patients were identified. The most common type of AN was appendiceal mucinous neoplasm (83.9 %). Three patients with ulcerative colitis (9.7 %) had recurrence after surgical resection due to peritoneal seeding.
Conclusions
Incidence and recurrence of AN in patients with IBD is low. Further studies to compare AN in patients with and without IBD are needed to determine if IBD predisposes to development of this complication.
{"title":"Clinical characteristics and outcomes of appendiceal neoplasms in inflammatory bowel disease: A tertiary care center experience","authors":"Siri A. Urquhart, Luis E. Ospina Velasquez, John B. Kisiel, Nayantara Coelho-Prabhu","doi":"10.1016/j.clinre.2026.102778","DOIUrl":"10.1016/j.clinre.2026.102778","url":null,"abstract":"<div><h3>Background and Aims</h3><div>A direct causal association between inflammatory bowel disease (IBD) and appendiceal neoplasm (AN) is unclear.</div></div><div><h3>Methods</h3><div>Patients with IBD and AN were identified from 1992 to 2023 using bioinformatics and natural language processing tools.</div></div><div><h3>Results</h3><div>Thirty-one patients were identified. The most common type of AN was appendiceal mucinous neoplasm (83.9 %). Three patients with ulcerative colitis (9.7 %) had recurrence after surgical resection due to peritoneal seeding.</div></div><div><h3>Conclusions</h3><div>Incidence and recurrence of AN in patients with IBD is low. Further studies to compare AN in patients with and without IBD are needed to determine if IBD predisposes to development of this complication.</div></div>","PeriodicalId":10424,"journal":{"name":"Clinics and research in hepatology and gastroenterology","volume":"50 3","pages":"Article 102778"},"PeriodicalIF":2.4,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146112499","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-26DOI: 10.1016/j.clinre.2026.102776
Alice Dongier , Edouard Louis , Jean-Philippe Loly , Pierre Dandoy , Odile Warling , Anne Vijverman , Jean Delwaide
Background
Prognosis in decompensated cirrhosis is heterogeneous and may be influenced by cirrhosis-associated immune dysfunction.
Aims
To assess whether QuantiFERON-Monitor, a whole blood interferon-γ release assay, predicts short-term outcomes in patients with acute decompensated cirrhosis.
Methods
We conducted a prospective cohort study in two hospitals (March 2022-March 2023), enrolling 44 patients hospitalized for acute decompensated cirrhosis. QuantiFERON-Monitor testing measured interferon-γ release after immune stimulation during hospitalization. Patients were followed for 90 days for mortality, bacterial infection, and acute-on-chronic liver failure. Associations between interferon-gamma levels and outcomes were evaluated using Cox proportional hazards and logistic regression models.
Results
The median interferon-γ release was 56 IU/mL (1-366). Each 10 IU/mL increase was associated with a 12% relative reduction in 90-day risk of death or ACLF (HR 0.88, 95% CI 0.79-0.99; p=0.03). No deaths occurred in patients with Interferon-γ ≥ 100 IU/mL versus 39% mortality in those below (p=0.01). Interferon-γ levels were not significantly associated with infection or acute-on-chronic liver failure. Adding QuantiFERON-Monitor to the MELD-Na improved discrimination for early mortality or acute-on-chronic liver failure.
Conclusions
Baseline interferon-γ release measured by the QuantiFERON-Monitor is a prognostic marker of short-term poor outcome in acute decompensated cirrhosis, reflecting cellular immune dysfunction. This assay may complement existing prognostic tools. Further validation with a larger cohort is required.
{"title":"QuantiFERON-Monitor as prognostic marker of mortality in patients with decompensated cirrhosis: A prospective cohort study","authors":"Alice Dongier , Edouard Louis , Jean-Philippe Loly , Pierre Dandoy , Odile Warling , Anne Vijverman , Jean Delwaide","doi":"10.1016/j.clinre.2026.102776","DOIUrl":"10.1016/j.clinre.2026.102776","url":null,"abstract":"<div><h3>Background</h3><div>Prognosis in decompensated cirrhosis is heterogeneous and may be influenced by cirrhosis-associated immune dysfunction.</div></div><div><h3>Aims</h3><div>To assess whether QuantiFERON-Monitor, a whole blood interferon-γ release assay, predicts short-term outcomes in patients with acute decompensated cirrhosis.</div></div><div><h3>Methods</h3><div>We conducted a prospective cohort study in two hospitals (March 2022-March 2023), enrolling 44 patients hospitalized for acute decompensated cirrhosis. QuantiFERON-Monitor testing measured interferon-γ release after immune stimulation during hospitalization. Patients were followed for 90 days for mortality, bacterial infection, and acute-on-chronic liver failure. Associations between interferon-gamma levels and outcomes were evaluated using Cox proportional hazards and logistic regression models.</div></div><div><h3>Results</h3><div>The median interferon-γ release was 56 IU/mL (1-366). Each 10 IU/mL increase was associated with a 12% relative reduction in 90-day risk of death or ACLF (HR 0.88, 95% CI 0.79-0.99; p=0.03). No deaths occurred in patients with Interferon-γ ≥ 100 IU/mL versus 39% mortality in those below (p=0.01). Interferon-γ levels were not significantly associated with infection or acute-on-chronic liver failure. Adding QuantiFERON-Monitor to the MELD-Na improved discrimination for early mortality or acute-on-chronic liver failure.</div></div><div><h3>Conclusions</h3><div>Baseline interferon-γ release measured by the QuantiFERON-Monitor is a prognostic marker of short-term poor outcome in acute decompensated cirrhosis, reflecting cellular immune dysfunction. This assay may complement existing prognostic tools. Further validation with a larger cohort is required.</div></div>","PeriodicalId":10424,"journal":{"name":"Clinics and research in hepatology and gastroenterology","volume":"50 3","pages":"Article 102776"},"PeriodicalIF":2.4,"publicationDate":"2026-01-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146099936","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Intra-pancreatic fat deposition (IPFD) is associated with health issues, yet its distribution patterns across age and gender remain unclear. This study analyzed differences in computed tomography (CT)-based IPFD content among different age and gender groups.
Methods
A retrospective cohort of 1305 adults undergoing chest CT examinations was established. Pancreatic and splenic CT attenuation values were measured, pancreas-to-spleen CT ratio (P/S) and pancreas-to-spleen CT difference (P-S) were also calculated which served as indicators of IPFD. Pearson correlation analysis was employed to assess the relationship between each parameter and age stratified by sex. Multiple linear regression was applied to evaluate the independent effects of age and sex.
Results
Pancreatic fat-related CT parameters were negatively correlated with age (r = -0.527 to -0.467, p < 0.001). Compared to young adults aged 21–29 years, pancreatic CT attenuation and both the P/S ratio and P-S difference fallen markedly by the 51–59-year group. An even greater difference was observed in individuals over 70 years of age. The P/S ratio and P-S of males were significantly lower than female in each age group. Multiple linear regression showed that age were independent negative predictors of all parameters (p < 0.001), while gender was an independent influencing factor of the P/S ratio (β = 0.073, p = 0.004) and P-S (β = 0.072, P = 0.004), but had no independent predictive effect on the unadjusted pancreatic CT value.
Conclusion
IPFD shows a gradual increase with advancing age and is higher in males compared to females.
{"title":"Age and sex differences in intrapancreatic fat deposition: A cross-sectional CT study","authors":"Yiping Zhang, Dingzhe Zhang, Rongzhou Wang, Rui Yu, Yu Wang, Jianhua Wang, Xiao Chen","doi":"10.1016/j.clinre.2026.102770","DOIUrl":"10.1016/j.clinre.2026.102770","url":null,"abstract":"<div><h3>Background/aims</h3><div>Intra-pancreatic fat deposition (IPFD) is associated with health issues, yet its distribution patterns across age and gender remain unclear. This study analyzed differences in computed tomography (CT)-based IPFD content among different age and gender groups.</div></div><div><h3>Methods</h3><div>A retrospective cohort of 1305 adults undergoing chest CT examinations was established. Pancreatic and splenic CT attenuation values were measured, pancreas-to-spleen CT ratio (P/S) and pancreas-to-spleen CT difference (P-S) were also calculated which served as indicators of IPFD. Pearson correlation analysis was employed to assess the relationship between each parameter and age stratified by sex. Multiple linear regression was applied to evaluate the independent effects of age and sex.</div></div><div><h3>Results</h3><div>Pancreatic fat-related CT parameters were negatively correlated with age (<em>r</em> = -0.527 to -0.467, <em>p</em> < 0.001). Compared to young adults aged 21–29 years, pancreatic CT attenuation and both the P/S ratio and P-S difference fallen markedly by the 51–59-year group. An even greater difference was observed in individuals over 70 years of age. The P/S ratio and P-S of males were significantly lower than female in each age group. Multiple linear regression showed that age were independent negative predictors of all parameters (<em>p</em> < 0.001), while gender was an independent influencing factor of the P/S ratio (β = 0.073, <em>p</em> = 0.004) and P-S (β = 0.072, <em>P</em> = 0.004), but had no independent predictive effect on the unadjusted pancreatic CT value.</div></div><div><h3>Conclusion</h3><div>IPFD shows a gradual increase with advancing age and is higher in males compared to females.</div></div>","PeriodicalId":10424,"journal":{"name":"Clinics and research in hepatology and gastroenterology","volume":"50 3","pages":"Article 102770"},"PeriodicalIF":2.4,"publicationDate":"2026-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146050600","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-19DOI: 10.1016/j.clinre.2026.102768
Paulina Chodnicka, Elżbieta Jurkiewicz, Kamil Janowski, Maria Janowska, Agnieszka Pytlewska, Małgorzata Gołuch, Małgorzata Markiewicz-Kijewska, Maciej Pronicki, Wiesława Grajkowska, Piotr Socha
Objectives
Liver fibrosis staging in pediatric patients traditionally relies on invasive methods, such as liver biopsy, which pose risks and limitations. Magnetic Resonance Elastography (MRE) has emerged as a promising noninvasive alternative. This study aimed to validate the use of MRE in pediatric liver diseases and assess its diagnostic accuracy.
Methods
A total of 110 participants (61 with autoimmune hepatitis (AIH), 33 post-liver transplantation (LTx), and 16 healthy controls) underwent MRE examinations. Liver biopsies were performed based on ESPGHAN indications in patients with AIH and according to institutional post-transplant protocols in LTx patients. Biochemical data were collected including ALT (alanine aminotransferase), AST (aspartate transaminase), INR (international normalized ratio), bilirubin, and platelet counts. The APRI (aspartate aminotransferase to platelet ratio index) and FIB 4 (Fibrosis Index Based on 4 Factors) were calculated.
Results
In AIH patients MRE showed a sensitivity of 76.2% and specificity of 84.6% for moderete to severe fibrosis, incomplete cirrhosis and cirrhosis (Ishak 4–6, AUC 0.828, cutoff 3.28 kPa) and a sensitivity of 80% and specificity of 88.9% for incomplete cirrhosis and cirrhosis (Ishak 5–6, AUC 0.896, cutoff 3.68 kPa). In LTx patients, MRE demonstrated a sensitivity of 80% and specificity of 91.3% for moderete to severe fibrosis and cirrhosis (Ishak 4–6, AUC 0.865, cutoff 3.1 kPa). Inter-observer agreement for MRE was excellent (ICC(3,1) of 0.988)
Conclusions
MRE is a valuable noninvasive tool offering an accurate assessment of fibrosis. Further research is warranted to expand MRE's utility across diverse pediatric liver conditions. This validation of the MRE highlights its potential to enhance clinical decision-making and patient care in pediatric hepatology.
{"title":"Sensitivity and specificity of magnetic resonance elastography in liver diseases in the pediatric age group","authors":"Paulina Chodnicka, Elżbieta Jurkiewicz, Kamil Janowski, Maria Janowska, Agnieszka Pytlewska, Małgorzata Gołuch, Małgorzata Markiewicz-Kijewska, Maciej Pronicki, Wiesława Grajkowska, Piotr Socha","doi":"10.1016/j.clinre.2026.102768","DOIUrl":"10.1016/j.clinre.2026.102768","url":null,"abstract":"<div><h3>Objectives</h3><div>Liver fibrosis staging in pediatric patients traditionally relies on invasive methods, such as liver biopsy, which pose risks and limitations. Magnetic Resonance Elastography (MRE) has emerged as a promising noninvasive alternative. This study aimed to validate the use of MRE in pediatric liver diseases and assess its diagnostic accuracy.</div></div><div><h3>Methods</h3><div>A total of 110 participants (61 with autoimmune hepatitis (AIH), 33 post-liver transplantation (LTx), and 16 healthy controls) underwent MRE examinations. Liver biopsies were performed based on ESPGHAN indications in patients with AIH and according to institutional post-transplant protocols in LTx patients. Biochemical data were collected including ALT (alanine aminotransferase), AST (aspartate transaminase), INR (international normalized ratio), bilirubin, and platelet counts. The APRI (aspartate aminotransferase to platelet ratio index) and FIB 4 (Fibrosis Index Based on 4 Factors) were calculated.</div></div><div><h3>Results</h3><div>In AIH patients MRE showed a sensitivity of 76.2% and specificity of 84.6% for moderete to severe fibrosis, incomplete cirrhosis and cirrhosis (Ishak 4–6, AUC 0.828, cutoff 3.28 kPa) and a sensitivity of 80% and specificity of 88.9% for incomplete cirrhosis and cirrhosis (Ishak 5–6, AUC 0.896, cutoff 3.68 kPa). In LTx patients, MRE demonstrated a sensitivity of 80% and specificity of 91.3% for moderete to severe fibrosis and cirrhosis (Ishak 4–6, AUC 0.865, cutoff 3.1 kPa). Inter-observer agreement for MRE was excellent (ICC(3,1) of 0.988)</div></div><div><h3>Conclusions</h3><div>MRE is a valuable noninvasive tool offering an accurate assessment of fibrosis. Further research is warranted to expand MRE's utility across diverse pediatric liver conditions. This validation of the MRE highlights its potential to enhance clinical decision-making and patient care in pediatric hepatology.</div></div>","PeriodicalId":10424,"journal":{"name":"Clinics and research in hepatology and gastroenterology","volume":"50 3","pages":"Article 102768"},"PeriodicalIF":2.4,"publicationDate":"2026-01-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146017486","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-19DOI: 10.1016/j.clinre.2026.102769
Katharina Köstenbauer , Theresa Bauer , Patrick Greimel , Tanja Strini , Axel Schlagenhauf , Jörg Jahnel
{"title":"Muricholic acids and autotaxin in intrahepatic cholestasis of pregnancy: A case-control study","authors":"Katharina Köstenbauer , Theresa Bauer , Patrick Greimel , Tanja Strini , Axel Schlagenhauf , Jörg Jahnel","doi":"10.1016/j.clinre.2026.102769","DOIUrl":"10.1016/j.clinre.2026.102769","url":null,"abstract":"","PeriodicalId":10424,"journal":{"name":"Clinics and research in hepatology and gastroenterology","volume":"50 2","pages":"Article 102769"},"PeriodicalIF":2.4,"publicationDate":"2026-01-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146017427","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-13DOI: 10.1016/j.clinre.2026.102767
Sarvesh Sabarathinam , Nila Ganamurali , K K S Kartheekeyan , Manoj Kumar Narasimhan , Evelyn Sharon Sukumaran
{"title":"FXR dysregulation as the metabolic nexus driving cholesterol gallstone disease","authors":"Sarvesh Sabarathinam , Nila Ganamurali , K K S Kartheekeyan , Manoj Kumar Narasimhan , Evelyn Sharon Sukumaran","doi":"10.1016/j.clinre.2026.102767","DOIUrl":"10.1016/j.clinre.2026.102767","url":null,"abstract":"","PeriodicalId":10424,"journal":{"name":"Clinics and research in hepatology and gastroenterology","volume":"50 2","pages":"Article 102767"},"PeriodicalIF":2.4,"publicationDate":"2026-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145988185","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Primary sclerosing cholangitis (PSC) is strongly associated with inflammatory bowel disease (IBD), with up to 70% of PSC patients having concomitant IBD (PSC-IBD). Fecal Calprotectin (FC) is a validated surrogate biomarker of intestinal inflammation in IBD. Emerging evidence suggests that FC may also reflect biliary inflammation in PSC.
Aim
This study aimed to compare FC concentrations in patients with PSC-IBD versus IBD only.
Methods
A systematic literature search was performed (PROSPERO registration no. CRD42024600985). Studies reporting FC levels in both PSC-IBD and IBD-only patients were included. The outcome of interest was the difference in mean FC concentration between the two groups.
Results
Seven studies met the inclusion criteria. There was no significant difference in the mean FC levels between PSC-IBD and IBD patients (-5.10, 95% confidence interval [CI] -45.40 to -35.2; p= 0.8). The findings remained non-significant when endoscopic remission was considered (12.82, 95% CI -19.33 to 44.97; p= 0.43).
Conclusions
FC levels did not significantly differ between PSC-IBD and IBD groups. The available evidence is limited and heterogeneous. Larger, well-designed studies are needed to determine whether FC can serve as a surrogate biomarker of PSC progression, particularly in patients with endoscopic remission of colitis or without concomitant IBD.
背景：原发性硬化性胆管炎（PSC）与炎症性肠病（IBD）密切相关，高达70%的PSC患者伴有IBD （PSC-IBD）。粪钙保护蛋白（FC）是一种有效的IBD肠道炎症替代生物标志物。新出现的证据表明FC也可能反映PSC的胆道炎症。目的：本研究旨在比较PSC-IBD患者与单纯IBD患者的FC浓度。方法：进行系统的文献检索(PROSPERO注册号：；CRD42024600985)。研究报告了PSC-IBD和仅ibd患者的FC水平。我们感兴趣的结果是两组间FC平均浓度的差异。结果：7项研究符合纳入标准。PSC-IBD和IBD患者的平均FC水平无显著差异（-5.10,95%可信区间[CI] -45.40至-35.2;p= 0.8）。当考虑内镜缓解时，结果仍然不显著（12.82,95% CI -19.33至44.97;p= 0.43）。结论：FC水平在PSC-IBD组和IBD组之间无显著差异。可获得的证据是有限的和不同的。需要更大规模、设计良好的研究来确定FC是否可以作为PSC进展的替代生物标志物，特别是在内镜下结肠炎缓解或无合并IBD的患者中。
{"title":"Fecal calprotectin in patients with concomitant primary sclerosing cholangitis and inflammatory bowel disease: a systematic review and meta-analysis","authors":"Giorgia Burrelli Scotti , Fabrizio Zullo , Marco Mattana , Francesco Covotta , Emanuela Ribichini , Domenico Alvaro , Vincenzo Cardinale","doi":"10.1016/j.clinre.2026.102764","DOIUrl":"10.1016/j.clinre.2026.102764","url":null,"abstract":"<div><h3>Background</h3><div>Primary sclerosing cholangitis (PSC) is strongly associated with inflammatory bowel disease (IBD), with up to 70% of PSC patients having concomitant IBD (PSC-IBD). Fecal Calprotectin (FC) is a validated surrogate biomarker of intestinal inflammation in IBD. Emerging evidence suggests that FC may also reflect biliary inflammation in PSC.</div></div><div><h3>Aim</h3><div>This study aimed to compare FC concentrations in patients with PSC-IBD versus IBD only.</div></div><div><h3>Methods</h3><div>A systematic literature search was performed (PROSPERO registration no. CRD42024600985). Studies reporting FC levels in both PSC-IBD and IBD-only patients were included. The outcome of interest was the difference in mean FC concentration between the two groups.</div></div><div><h3>Results</h3><div>Seven studies met the inclusion criteria. There was no significant difference in the mean FC levels between PSC-IBD and IBD patients (-5.10, 95% confidence interval [CI] -45.40 to -35.2; p= 0.8). The findings remained non-significant when endoscopic remission was considered (12.82, 95% CI -19.33 to 44.97; p= 0.43).</div></div><div><h3>Conclusions</h3><div>FC levels did not significantly differ between PSC-IBD and IBD groups. The available evidence is limited and heterogeneous. Larger, well-designed studies are needed to determine whether FC can serve as a surrogate biomarker of PSC progression, particularly in patients with endoscopic remission of colitis or without concomitant IBD.</div></div>","PeriodicalId":10424,"journal":{"name":"Clinics and research in hepatology and gastroenterology","volume":"50 2","pages":"Article 102764"},"PeriodicalIF":2.4,"publicationDate":"2026-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145988189","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Comment on “Comparison of repeat hepatectomy with radiofrequency ablation for the survival of hepatocellular carcinoma with solitary intrahepatic recurrence after hepatectomy”","authors":"Kanishka Harariya , Thakur Rohit Singh , Ankita Kalra , Swarupanjali Padhi , Fayaz Ahamed","doi":"10.1016/j.clinre.2026.102762","DOIUrl":"10.1016/j.clinre.2026.102762","url":null,"abstract":"","PeriodicalId":10424,"journal":{"name":"Clinics and research in hepatology and gastroenterology","volume":"50 2","pages":"Article 102762"},"PeriodicalIF":2.4,"publicationDate":"2026-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145988116","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-13DOI: 10.1016/j.clinre.2026.102763
Qunxiang Cao , Siyang Chen , Yutian Zhang , Juping Yang , Zhaohui Wang
<div><h3>Objective</h3><div>This study investigates the incidence, clinical characteristics, and risk factors of drug-induced liver injury (DILI) in cancer patients undergoing multiple courses of common chemotherapy drugs, providing evidence for developing DILI prevention and control strategies in clinical practice.</div></div><div><h3>Methods</h3><div>A retrospective cohort study included 165 cancer patients who received multiple courses of common chemotherapy drugs between January 2023 and January 2025. Participants were divided into a study group (<em>n</em> = 45, DILI occurrence) and a control group (<em>n</em> = 120, no DILI occurrence) based on DILI development. Baseline patient data, chemotherapy regimens, and liver function indicators were collected. Univariate analysis screened potential risk factors, while multivariate logistic regression validated independent risk factors. Spearman's rank correlation analyzed associations between risk factors and DILI severity.</div></div><div><h3>Results</h3><div>The overall DILI incidence among 165 patients was 27.27% (45/165), predominantly moderate in severity. Distribution by grade was: Grade 1 (mild) 14 cases (31.11%), Grade 2 (moderate) 24 cases (53.33%), Grade 3 (severe) 7 cases (15.56%), with no Grade 4 injury. Comparison of baseline characteristics between groups revealed higher DILI incidence among patients aged ≥60 years, with alcohol consumption history, viral hepatitis history, underlying liver disease, ≥3 chemotherapy drugs, and without prophylactic hepatoprotective/cholagogue use (all <em>p</em> < 0.05). Post-chemotherapy, the study group exhibited significantly higher levels of ALT, AST, ALP, GGT, and TBIL compared to the control group (all <em>p</em> < 0.001). Multivariate analysis confirmed that age ≥60 years (OR=2.964, 95% CI: 1.247–7.043, <em>p</em> = 0.014), history of alcohol consumption (OR=3.684, 95% CI: 1.523–8.912, <em>p</em> = 0.004), history of viral hepatitis (OR=3.116, 95% CI: 1.116–8.696, <em>p</em> = 0.030), underlying liver disease (OR=3.293, 95% CI: 1.312–8.266, <em>p</em> = 0.011), use of ≥3 chemotherapy drugs (OR=1.666, 95% CI: 1.031–2.690, <em>p</em> = 0.037), and lack of prophylactic hepatoprotective and cholagogue medication use (OR=0.326, 95% CI: 0.137–0.772, <em>p</em> = 0.011) were identified as independent risk factors for DILI occurrence. Spearman analysis revealed positive correlations between age, alcohol consumption history, viral hepatitis history, underlying liver disease, and number of chemotherapy drugs with DILI severity, while a negative correlation was observed between hepatoprotective and cholagogue drug use and DILI severity.</div></div><div><h3>Conclusion</h3><div>Tumor patients undergoing multiple courses of common chemotherapy drugs exhibit a high incidence of DILI, predominantly moderate in severity. Age ≥60 years, history of alcohol consumption, history of viral hepatitis, underlying liver disease, use of ≥3 chemotherapy drugs, and lac
{"title":"Clinical characteristics and risk factors of drug-induced hepatotoxicity in cancer patients following repeated chemotherapy cycles","authors":"Qunxiang Cao , Siyang Chen , Yutian Zhang , Juping Yang , Zhaohui Wang","doi":"10.1016/j.clinre.2026.102763","DOIUrl":"10.1016/j.clinre.2026.102763","url":null,"abstract":"<div><h3>Objective</h3><div>This study investigates the incidence, clinical characteristics, and risk factors of drug-induced liver injury (DILI) in cancer patients undergoing multiple courses of common chemotherapy drugs, providing evidence for developing DILI prevention and control strategies in clinical practice.</div></div><div><h3>Methods</h3><div>A retrospective cohort study included 165 cancer patients who received multiple courses of common chemotherapy drugs between January 2023 and January 2025. Participants were divided into a study group (<em>n</em> = 45, DILI occurrence) and a control group (<em>n</em> = 120, no DILI occurrence) based on DILI development. Baseline patient data, chemotherapy regimens, and liver function indicators were collected. Univariate analysis screened potential risk factors, while multivariate logistic regression validated independent risk factors. Spearman's rank correlation analyzed associations between risk factors and DILI severity.</div></div><div><h3>Results</h3><div>The overall DILI incidence among 165 patients was 27.27% (45/165), predominantly moderate in severity. Distribution by grade was: Grade 1 (mild) 14 cases (31.11%), Grade 2 (moderate) 24 cases (53.33%), Grade 3 (severe) 7 cases (15.56%), with no Grade 4 injury. Comparison of baseline characteristics between groups revealed higher DILI incidence among patients aged ≥60 years, with alcohol consumption history, viral hepatitis history, underlying liver disease, ≥3 chemotherapy drugs, and without prophylactic hepatoprotective/cholagogue use (all <em>p</em> < 0.05). Post-chemotherapy, the study group exhibited significantly higher levels of ALT, AST, ALP, GGT, and TBIL compared to the control group (all <em>p</em> < 0.001). Multivariate analysis confirmed that age ≥60 years (OR=2.964, 95% CI: 1.247–7.043, <em>p</em> = 0.014), history of alcohol consumption (OR=3.684, 95% CI: 1.523–8.912, <em>p</em> = 0.004), history of viral hepatitis (OR=3.116, 95% CI: 1.116–8.696, <em>p</em> = 0.030), underlying liver disease (OR=3.293, 95% CI: 1.312–8.266, <em>p</em> = 0.011), use of ≥3 chemotherapy drugs (OR=1.666, 95% CI: 1.031–2.690, <em>p</em> = 0.037), and lack of prophylactic hepatoprotective and cholagogue medication use (OR=0.326, 95% CI: 0.137–0.772, <em>p</em> = 0.011) were identified as independent risk factors for DILI occurrence. Spearman analysis revealed positive correlations between age, alcohol consumption history, viral hepatitis history, underlying liver disease, and number of chemotherapy drugs with DILI severity, while a negative correlation was observed between hepatoprotective and cholagogue drug use and DILI severity.</div></div><div><h3>Conclusion</h3><div>Tumor patients undergoing multiple courses of common chemotherapy drugs exhibit a high incidence of DILI, predominantly moderate in severity. Age ≥60 years, history of alcohol consumption, history of viral hepatitis, underlying liver disease, use of ≥3 chemotherapy drugs, and lac","PeriodicalId":10424,"journal":{"name":"Clinics and research in hepatology and gastroenterology","volume":"50 3","pages":"Article 102763"},"PeriodicalIF":2.4,"publicationDate":"2026-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145988018","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-13DOI: 10.1016/j.clinre.2026.102766
Francisco Baez , Damian Soria , Mario Contin , Carolina Caniffi , Valeria Tripodi
{"title":"Modeling the importance of coenzyme Q9, glutathione and mitochondrial complex activity in a high fat diet model by a multivariate approach","authors":"Francisco Baez , Damian Soria , Mario Contin , Carolina Caniffi , Valeria Tripodi","doi":"10.1016/j.clinre.2026.102766","DOIUrl":"10.1016/j.clinre.2026.102766","url":null,"abstract":"","PeriodicalId":10424,"journal":{"name":"Clinics and research in hepatology and gastroenterology","volume":"50 3","pages":"Article 102766"},"PeriodicalIF":2.4,"publicationDate":"2026-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145988208","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号